Breakthrough The British prostate cancer test can prevent the need for biopsy in 80 pcs of men

According to a study, a British prostate cancer test can prevent the need for biopsy in four of the five cases.

The episode PSE PSE Next Generation Blood Test uses progress in technology to identify prostate cancer, the most common form of the disease in men in the UK.

The test, made by Oxford Biodynamics, has an accuracy of 94 percent in identifying prostate cancer, a dramatic jump compared to the standard test along, which is thought that it is correct in just half of the cases.

It is crucial that a peer -reviewed study that must be published in the medical magazine cancers accepts the findings that up to 80 percent of patients could possibly avoid unnecessary prostate biopsy – considered an often invasive procedure as one of the largest stumbling blocks in men who are tested in the first place.

The study concludes: “In models, up to 79.1 percent of patients can safely postpone biopsy based on PSE results, which emphasizes the potential of the test to reduce invasive procedures without endangering diagnostic safety.”

Dr. Alexandre Akoulitchev, Chief Scientific Officer at Oxford Biodynamics said: ‘This study builds on our earlier robust clinical validation work that demonstrated the use of Episwitch PSE as a precise, minimally invasive test that reduces clinicians and patients of the diagnosis of the diagnosis of the diagnosis of the diagnosis of the diagnosis of the diagnosis’

The paper said that the innovation could save the NHS considerably money by reducing the number of men sent for biopsies and MRI scans, reducing the pressure on the service.

The study thought this was translated into a saving of almost £ 1,000 per patient.

The conservative MP said he had tested himself after he was struck by the number of his friends struck by the disease

National Treasure Sir Stephen Fry, himself a former prostate cancer patient, has supported the Daily Mail campaign for a pee program for men with a risk

Oliver Kemp, from Prostate Cancer Research, said that reducing the number of biopsies reduced stress for men reduced

Oliver Kemp, Chief Executive of UK Charity Prostate Cancer Research (PCR), said: ‘This study shows how smarter testing can save millions and at the same time improve care for patients.

“Reducing unnecessary biopsies and scans means less stress for men and more capacity in the system.”

Oxford Biodynamics collaborated with leading researchers and clinicians on the Imperial NHS Trust, Imperial College London and the University of East Anglia to produce episode.

It is used after a PSA test – which means that prostate -specific antigen, which identifies or the protein levels produced by the gland are increased – and measures five markers to identify the chance that cancer is present.

The company’s headquarters were visited in February of this year by former Prime Minister Rishi Sunak, because he calls for a targeted national screening program for men who run the most risk of prostate cancer.

In the government, Mr Sunak with Charity PCR announced a screening study of £ 42 million to find ways to detect prostate cancer earlier.

But it is hoped that a national screening program would be the most effective way to prevent unnecessary deaths.

The post has long been campaigning for a national rollout, a cause supported by Sir Stephen Fry, a former prostate cancer patient.

The British National Screening Committee has been busy, among other things, to reconsider the test policy after the news last year of the diagnosis of Sir Chris Hoy with the terminal disease.

Prostate cancer influences the most black men and people with family history. It is often symptomless, which means that early detection is crucial when stopping the spread of the disease.

Earlier this week, newsreader Dermot Murnaghan revealed that he is fighting against stage-four prostate cancer.